Free Trial

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

-11.63 (-2.19%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
486,416 shs
Average Volume
452,925 shs
Market Capitalization
$42.82 billion
P/E Ratio
Dividend Yield
Price Target

IDEXX Laboratories MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
11.9% Upside
$580.38 Price Target
Short Interest
2.07% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.53mentions of IDEXX Laboratories in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$108,160 Sold Last Quarter
Proj. Earnings Growth
From $11.03 to $12.57 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.29 out of 5 stars

Medical Sector

210th out of 921 stocks

Diagnostic Substances Industry

4th out of 13 stocks

IDXX stock logo

About IDEXX Laboratories Stock (NASDAQ:IDXX)

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Stock Price History

IDXX Stock News Headlines

Q1 2024 IDEXX Laboratories Inc Earnings Call
Idexx 1Q Net Up; Lowers Guidance for The Year
Idexx: Q1 Earnings Snapshot
IDEXX Laboratories earnings preview: what Wall Street is expecting
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Diagnostic substances
Health Care Equipment
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
9 Analysts


Net Income
$845.04 million
Pretax Margin


Sales & Book Value

Annual Sales
$3.66 billion
Cash Flow
$11.17 per share
Book Value
$17.88 per share


Free Float
Market Cap
$43.37 billion

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

IDXX Stock Analysis - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price target for 2024?

9 brokerages have issued 12-month price objectives for IDEXX Laboratories' stock. Their IDXX share price targets range from $460.00 to $650.00. On average, they expect the company's stock price to reach $580.38 in the next twelve months. This suggests a possible upside of 11.9% from the stock's current price.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2024?

IDEXX Laboratories' stock was trading at $555.05 at the beginning of 2024. Since then, IDXX shares have decreased by 6.6% and is now trading at $518.44.
View the best growth stocks for 2024 here

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our IDXX earnings forecast

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings results on Monday, February, 5th. The company reported $2.32 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.20. The business had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a net margin of 23.26% and a trailing twelve-month return on equity of 63.66%. IDEXX Laboratories's revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the company earned $2.05 EPS.
Read the conference call transcript

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY24 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of $10.82-$11.20 for the period, compared to the consensus estimate of $11.17. The company issued revenue guidance of $3.895-$3.965 billion, compared to the consensus revenue estimate of $3.99 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.26%), Bamco Inc. NY (2.55%), Blair William & Co. IL (1.44%), Principal Financial Group Inc. (0.92%), Bank of New York Mellon Corp (0.76%) and Williams Jones Wealth Management LLC. (0.43%). Insiders that own company stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, George Fennell, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt and Sophie V Vandebroek.
View institutional ownership trends

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IDXX) was last updated on 5/21/2024 by Staff

From Our Partners